Literature DB >> 7723659

Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260.

L S McDaniel1, B A Ralph, D O McDaniel, D E Briles.   

Abstract

Pneumococcal surface protein A (PspA) is a virulence factor of Streptococcus pneumoniae that can elicit a protective antibody response. The pspA gene of strain Rx1 encodes a 65 kDa molecule composed of 588 amino acids. The N-terminal 288 amino acids are highly charged, and predict an alpha-helical coiled-coil protein structure. All monoclonal antibodies (MAbs) to PspA, obtained by screening against whole pneumococci, bind to the alpha-helical region of PspA, suggesting that this region is surface exposed. The C-terminal 217 amino acids of PspA contain the surface anchor of PspA and does not appear to be alpha-helical. In the middle of the molecule is a proline-rich region that is thought to traverse the cell wall. In this study we have mapped the immunogenic epitopes detected by 9 MAbs that were made against strain Rx1 PspA. Five of the MAb also react with the PspA of mouse virulent strain WU2. All epitopes were found in one of two portions of the alpha-helical region. One comprised the first 115 amino acids, and the other was within amino acids 192 and 260. The five MAbs that recognize WU2 PspA, but not the remaining four MAbs, were protective against strain WU2. The epitopes detected by four of the five protective MAbs mapped to region 192 to 260 of Rx1 PspA. The existence of protective epitopes in this region was confirmed by demonstrating that mice immunized with the cloned fragment containing these residues were protected from fatal infection with WU2. Since amino acids 192 to 260 are in the region of PspA anticipated to be adjacent to the cell wall, and probably well covered by capsule, the means by which antibodies to the region lead to protection is not obvious.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7723659     DOI: 10.1006/mpat.1994.1078

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  58 in total

1.  Immunization with truncated recombinant protein SpaC of Erysipelothrix rhusiopathiae strain 715 serovar 18 confers protective immunity against challenge with various serovars.

Authors:  Ho To; Shuichi Someno; Shinya Nagai; Tomohiro Koyama; Tetsuji Nagano
Journal:  Clin Vaccine Immunol       Date:  2010-10-06

2.  Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades.

Authors:  Eliane N Miyaji; Daniela M Ferreira; Alexandre P Y Lopes; M Cristina C Brandileone; Waldely O Dias; Luciana C C Leite
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

Review 3.  Pneumococcal and influenza vaccination: current situation and future prospects.

Authors:  F Horwood; J Macfarlane
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

4.  Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae.

Authors:  Melanie Abeyta; Gail G Hardy; Janet Yother
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

5.  Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae.

Authors:  Bing Ren; Alexander J Szalai; Orlanda Thomas; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

6.  Acquired, but not innate, immune responses to Streptococcus pneumoniae are compromised by neutralization of CD40L.

Authors:  Y i Hwang; M H Nahm; D E Briles; D Thomas; J M Purkerson
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

7.  Immunization with PspA incorporated into a poly(ethylene oxide) matrix elicits protective immunity against Streptococcus pneumoniae.

Authors:  Quincy C Moore; LaShundra Johnson; Michael Repka; Larry S McDaniel
Journal:  Clin Vaccine Immunol       Date:  2007-04-25

8.  Truncated surface protective antigen (SpaA) of Erysipelothrix rhusiopathiae serotype 1a elicits protection against challenge with serotypes 1a and 2b in pigs.

Authors:  Y Imada; N Goji; H Ishikawa; M Kishima; T Sekizaki
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

9.  A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).

Authors:  Kristopher R Genschmer; Mary Ann Accavitti-Loper; David E Briles
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

10.  Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.

Authors:  Carolina Salcedo-Rivillas; Anne-Sophie Debrie; Eliane Namie Miyaji; Jorge M C Ferreira; Isaías Raw; Camille Locht; Paulo L Ho; Nathalie Mielcarek; Maria Leonor S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2014-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.